Cargando…
REL-1017 (Esmethadone) May Rapidly Reduce Dissociative Symptoms in Adults With Major Depressive Disorder Unresponsive to Standard Antidepressants: A Report of 2 Cases
Autores principales: | Guidetti, Clotilde, Serra, Giulia, Pani, Luca, Pappagallo, Marco, Maglio, Gino, Trasolini, Monia, De Martin, Sara, Mattarei, Andrea, Bifari, Francesco, Folli, Franco, Manfredi, Paolo L., Fava, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426728/ https://www.ncbi.nlm.nih.gov/pubmed/35943402 http://dx.doi.org/10.1097/JCP.0000000000001583 |
Ejemplares similares
-
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
por: Fava, Maurizio, et al.
Publicado: (2023) -
REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats
por: Bifari, Francesco, et al.
Publicado: (2022) -
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
por: Stahl, Stephen M., et al.
Publicado: (2022) -
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin
por: Bettini, Ezio, et al.
Publicado: (2022) -
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
por: Bettini, Ezio, et al.
Publicado: (2022)